H.R. 4993: Joe Fiandra Access to Home Infusion Act of 2025

This bill, known as the Joe Fiandra Access to Home Infusion Act of 2025, aims to amend the Social Security Act to extend Medicare coverage to specific medical equipment and medications used for home infusion therapy. Here are the main components of the bill:

Overview of Coverage

The bill proposes that starting one year after its enactment, Medicare will cover:

• External infusion pumps: Devices used to deliver medication into a patient's body.
• Home infusion drugs: Medications that need to be administered using these devices.
• Associated supplies: Items needed to facilitate the delivery of these drugs that meet safety and effectiveness requirements.

Criteria for Coverage

For these devices and medications to be covered under Medicare, specific criteria must be met:

• The prescribing information from the FDA must indicate that the infusion drug should be administered by or under the supervision of a healthcare professional.
• A qualified home infusion therapy supplier must administer or supervise the administration of the drug safely in the patient's home.
• The drug must need to be infused at least 12 times per year either intravenously or subcutaneously, or at infusion rates that necessitate the use of an external infusion pump.

Patient Notification

The bill also mandates that the Secretary of Health and Human Services inform patients about the cost-sharing involved in electing for home infusion therapy. This information will allow patients to compare their costs with those of other settings where infusion drugs are provided, ensuring transparency in their healthcare choices.

Implications

This legislation is designed to improve access to necessary medical treatments for patients who require ongoing medication but prefer or need to receive that treatment at home rather than in a clinical setting.

Relevant Companies

• ABT (Abbott Laboratories): As a leading manufacturer of medical devices, Abbott could see increased demand for its infusion pumps.
• MDT (Medtronic plc): Medtronic, known for its medical technology solutions, might benefit from greater utilization of its infusion technology in home settings.
• PFE (Pfizer Inc.): Pfizer could be affected as it manufactures various medications that may qualify for home infusion under this bill.